1. October E-learn Call: Visual Design for Powerful Presentations Sophy Wong (East Bay AETC)

2. Objectives By the end of this session, participants will be able to: Discuss and practice using 3 visual presentation design principles Evaluate 2 example presentation slides and recommend 2 ways to increase their visual impact Create your own awesome, high-impact slide

3. for Powerful Presentations! Sophy Wong, MD

4. objectives process & principles slide makeover s design a good slide

7. simplicity

8. focus

9. objectives process & principles slide makeover s design a good slide

10. 1. focus

13. high impact visuals

14. clear fonts

15. dark on light

16. (very) light on dark

17. empty space

20. 2. repetition

21. same fonts same colors same design

22. slide master

24. Does this enhance my central point?

25. …or does this?

26. 3. alignment

27. Keep it together text boxes tables grids

30. objectives process & principles slide makeover s design a good slide

31. bullet point makeover

32. Potential Benefits of Early Therapy (CD4 count >500 cells/µL)  Cohort study data show survival benefit if ART initiated at CD4 count >500 cells/µL  Earlier ART may prevent HIV-related end organ damage; deferred ART may not reliably repair damage acquired earlier  Increasing evidence of direct HIV effects on various end organs and indirect effects via HIV-associated inflammation  End organ damage occurs at all stages of infection October 2011www.aidsetc.org 32

33. Potential Benefits of Early Therapy (CD4 count >500 cells/µL) (2)  Potential decrease in risk of many complications, including:  HIV-associated nephropathy  Liver disease progression from hepatitis B or hepatitis C  Cardiovascular disease  Malignancies (AIDS defining and non-AIDS defining)  Neurocognitive decline  Blunted immunological response owing to ART initiation at older age  Persistent T-cell activation and inflammation October 2011www.aidsetc.org 33

34. Potential Benefits of Early Therapy (CD4 count >500 cells/µL) (3)  Prevention of sexual and bloodborne transmission of HIV  Prevention of mother-to-child transmission of HIV October 2011www.aidsetc.org 34

35. Potential Limitations of Early Therapy (CD4 count >500 cells/µL)  ARV-related toxicities  Drug resistance  Nonadherence to ART  Cost October 2011www.aidsetc.org 35

36. When to start ↑ CD4 +stay healthy  transmissio n -adherence  OIs -drug toxicity -resistance -lack of options

37. graph makeover

38. Source: Centers for Disease Control and Prevention (CDC). eHARS. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [2006-2010]. Percentage of Newly Reported HIV (non-AIDS) Cases By Race/Ethnicity, Alameda County 2006-2010

39. HIV by race/ethnicity, 2008

42. http://www.dhcs.ca.gov/Pages/HepatitisC.aspx

43. CA hep C treatment algorithm: handout! Getty Images

44. Shutterstock.com

45. CA hep C treatment algorithm mild liver disease wait cirrhosis, cryos vasculitis IFN-ineligible: SOF+Rib x24wks IFN-eligible: SOF+Rib+IFN X12wks

46. objectives process & principles slide makeover s design a good slide

47. 1. master slide 2. title slide 3. data slide

48. start fresh & focus

49. Questions?

50. Contact Any questions about the presentation:  Sophy Wong: sophy.wong@ucsf.edusophy.wong@ucsf.edu